Fig. 1.

TERRA Study Design. Enrolled set. ^aIn the prior PRN cohort, baseline visit was defined as the date of switch from the PRN to the T&E regimen (i.e., the date of the first ranibizumab injection under the T&E regimen) after at least 12 months of treatment on the PRN regimen; ^bIn the anti-VEGF-naïve cohort, the baseline visit for the anti-VEGF-naïve cohort was defined as the initiation date (and first ranibizumab injection) on the T&E regimen; at least 12 months of treatment on the T&E regimen was required for the anti-VEGF-naïve cohort. PRN pro re nata, T&E treat and extend, VEGF vascular endothelial growth factor